AIM ImmunoTech Inc (AIM)

AIM....................................https://stockcharts.com/sc3/ui/?s=AIM&p=w&b=5&g=0&id=p86431144783

This is-the PR we needed to breach $1 level

AIM ImmunoTech Reports Positive Mid-Year Interim Clinical Progress from Phase 2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca’s Imfinzi® (durvalumab) for the Treatment.

June 8, 2026

OCALA, Fla., June 08, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today reported positive progress in a mid-year update from the ongoing Phase 2 clinical study evaluating AIM’s drug Ampligen® (rintatolimod) combined with AstraZeneca’s anti-PD-L1 immune checkpoint inhibitor Imfinzi® (durvalumab) in the treatment of metastatic pancreatic cancer patients with stable disease post-FOLFIRINOX standard of care (the “DURIPANC” study) (see: ClinicalTrials.gov NCT05927142).

See: DURIPANC, 2026 Mid-Year Interim Clinical Progress Update

AIM recently announced enrollment of the final patient in the clinical trial, barring any disqualifying pre-treatment circumstances. The Company remains on track for a planned December 2026 evaluation of the clinical trial’s primary endpoint, Clinical Benefit Rate (“CBR”), defined as stable disease, partial response or complete response (progression-free disease) at 6 months (24 weeks) after start of combination therapy.

DURIPANC is a follow-up to a 57-subject Named Patient Program (“NPP”) of Ampligen as a monotherapy in late-stage pancreatic cancer, where Ampligen was associated with median survival of 19.7 months, which is an extension of median overall survival of 8.6 months when compared to the standard of care. The EAP subjects also reported improved quality of life.

AIM Chief Executive Officer Thomas Equels stated: “There is a clear need for an approved treatment that is both more effective and less toxic than what is currently available to people suffering with pancreatic cancer. Despite advances in chemotherapy, survival for these patients is too often short and agonizing. The published NPP data and the DURIPANC interim results support our belief that Ampligen has the potential to meaningfully extend survival and provide late-stage pancreatic cancer patients with a higher quality of life. For example, in the NPP stratification of subjects with immune marker Neutrophil/Lymphocyte ratios less than 4.5, we saw overall median survival of 34.8 months compared to 12.5 months for historical controls, for an improvement of 22.3 months – and with positive measures of quality of life. We are also diligently planning the next step in Ampligen's development, with an eye toward a pivotal Phase 3 clinical trial evaluating the experimental drug in combination with a PD-1 inhibitor in an effort to demonstrate its value across multiple endpoints, most importantly overall survival and progression-free survival. If a Phase 3 clinical trial was able to pair significant survival results with AIM’s impressive safety and tolerability profile, then it could position AIM as a leader in pancreatic cancer research potentially translational to the patient as a standard of care.”

The DURIPANC study is an investigator-initiated, exploratory, open-label, single-center study expected to enroll up to 25 subjects in the Phase 2 portion. The clinical trial is a joint collaboration between AIM, AstraZeneca and Erasmus Medical Center in the Netherlands. The primary objective of the study is the clinical benefit rate of the combination therapy. The secondary/exploratory objectives include assessing overall survival (OS) and progression-free survival (PFS); exploring immune-monitoring using available tissue biopsies and peripheral immune profiling; and assessing quality of life.

About AIM ImmunoTech Inc.
AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of its lead product, Ampligen® (rintatolimod), for the treatment of late-stage pancreatic cancer, a lethal and unmet global health problem. Ampligen is a dsRNA and highly selective TLR3 agonist immuno-modulator that has shown broad-spectrum activity in clinical trials.

For more information, please visit aimimmuno.com and connect with the Company on X, LinkedIn, and Facebook.

Link article

$AIM 🗞️

$0.94+ 😃

$AIM 💹

AIM......................p/m

$0.65+ 😃

$AIM 💹

Bought a little starter. Good luck Jus 🍀

$AIM

https://x.com/AimImmuno

Let's go aim!! Let's make .60 today

PotentiAl spike like otlk

AIM........................................https://stockcharts.com/sc3/ui/?s=AIM&p=w&b=5&g=0&id=p86431144783

AIM news .. AIM ImmunoTech Announces Emerging Ebola Opportunity for Ampligen Amid Escalating Global Health Concerns and WHO Emergency Declaration https://finance.yahoo.com/sectors/healthcare/articles/aim-immunotech-announces-emerging-ebola-124700404.html

AIM.................................https://stockcharts.com/sc3/ui/?s=AIM&p=w&b=5&g=0&id=p86431144783

Boo
You are 100% wrong so far on AIM.

I don't want to hear that the stock will increase. It's been 2-months and your suggestion that AIM was a good investment is 100% wrong.

Unless you are a paid promotor you may not want to give advice because your advice is and was wrong.
If you are a paid promoter you may want to look into SEC laws to make sure you are not PROMOTING a stock without disclosure, YES, even on this message board promotions can be classified as ILLEGAL without disclosure, AND YES, being have been arrested, charged and sentenced and fined for such illegal activity.

This one caught my eye for a bottom play. Almost there.

Looks like this company is CRUSHING it. lmao

AIM daily


Like your post.

To All The Nay Sayers that criticize on this board and all other boards I post on - I am ALWAYS proven right.

And YES, I am smarter than most people that criticize me on these boards.

The reason I am smarter is due to some very simple Investment 101 factors: (1) anytime a public company with a market cap less than $500 million has to raise capital they will have dilution and that always leads to lower stock price, (2) when a public company does not have funds invested it means the company should not be public, (3) ALL reverse mergers and SPACS have a never-ending stock price decline among a few other Investment 101 factors.

AND YES - I am always right when the top 3 Investment 101 Factors are adhered to.
AND YES - I make a very good living with my business and even more money investing in small and micro cap companies, but most of my profits are through short positions.
AND YES - I have lost money on some of my investments, but I would say 1 out of 10 investments is a loss, 9 out of 10 is a profit.
AND YES - I pay real taxes that include short term profit taxes on investments.
AND YES - I hope to pay twice as much in taxes every year until I die.

AND NO, all the naysayers that have and will continue to criticize me do not bother or upset me. I try really hard when I post on these boards to let people know about their investment and monies that they are likely to lose because of the 3 investment 101 factors.

I like to think I bring value and can save people money.

$AIM: Added 4k here at $12

Resumed trading.......... gimme $50 today


GO $AIM

$AIM: Halt city going on here............ RS'ed 100:1

And now trading...... $11.94 here on the halt

AIM ImmunoTech Resumes Trading on NYSE Americanhttps://t.co/QsPRSH3tS1 $AIM $AIMI pic.twitter.com/csYYHMo7UQ— AIM ImmunoTech (@AimImmuno) June 17, 2025

This has that moony potential after what happens with big RS's

https://finviz.com/news/82228/aim-immunotech-resumes-trading-on-nyse-american







GO $AIM

AIMI changed back to AIM. Moved to the AMEX from the OTC:

https://otce.finra.org/otce/dailyList?viewType=Deletions

AIMI one for 100 reverse split:

https://otce.finra.org/otce/dailyList?viewType=Symbol%2FName%20Changes

AIM changed to AIMI. Delisted from the AMEX to the OTC:

https://otce.finra.org/otce/dailyList?viewType=Additions

This thing is floating belly UP.

so,some interesting PR's lately...what is your personal opinion, hope etc. how this will play out in the end for us shareholders?
I know, no one knows, but yeah...what's is your feeling???

2 weeks ago, the PR that they will not proceed with the offering for now, already left many questions...

and then yesterdays double PR about the new director and his contract only for a few month till year end???somehow strange imo...

and the NYCE acceptance for listing compliance...!Top...

so yeah-what could, should, will be next???

A RS(hopefully not) or merger ,buyout etc.?

getting interesting in here:)

3m buys/2m sells/174k In between,big loading and few t trades,this could pop 100% easily

News,no offering until eoy filing(could be Fri)
Zero borrow,ppl saying big news coming,hype might run it up,I only have 10k in it as lotto play

They're steadily sliding down, but it might still make sense to monitor the situation for a while. Equels Thomas has made modest investments in his company’s stock this year—here’s the insider trading stats for reference: https://prismo.pro/stock/aim. Regardless, shares are purchased with the aim of yielding profit. Could it be they’re preparing for one of their drugs to finally hit the mark?

News is out

Guys what is the potential on this company?

AIM
AIM ImmunoTech Inc
0.265
-0.0508 (-16.09%)
Volume: 527,731
Day Range: 0.261 - 0.3223
Last Trade Time: 12:49:35 PM EDT
Total Trades: 888

AIM new 52 week low

AIM new 52 week low

https://www.otcmarkets.com/stock/AIM

https://www.otcmarkets.com/stock/AIM

https://www.otcmarkets.com/stock/AIM

https://www.otcmarkets.com/stock/AIM

https://otcbb.swingtradebot.com/equities/AIM

AIM
AIM ImmunoTech Inc
0.67
0.052 (8.41%)
Volume: 150,500
Day Range: 0.607 - 0.68
Last Trade Time: 8:00:00 PM EDT

AIM
AIM ImmunoTech Inc
0.488
-0.032 (-6.15%)
Volume: 176,585
Day Range: 0.48 - 0.5387
Last Trade Time: 8:00:00 PM EDT

AIM
AIM ImmunoTech Inc
0.4784
0.00 (0.00%)
Volume: 61,433
Day Range: 0.475 - 0.50
Last Trade Time: 8:00:00 PM EDT

https://www.otcmarkets.com/stock/AIM

AIM
AIM ImmunoTech Inc
0.5063
0.0263 (5.48%)
Volume: 62,250
Day Range: 0.47 - 0.49
Last Trade Time: 8:00:00 PM EDT

AIM
AIM ImmunoTech Inc
0.47
0.029 (6.58%)
Volume: 26,623
Day Range: 0.4301 - 0.4586
Last Trade Time: 8:00:00 PM EDT

AIM
AIM ImmunoTech Inc
0.53
0.035 (7.07%)
Volume: 292,608
Day Range: 0.4916 - 0.55
Last Trade Time: 8:00:00 PM EST

AIM
AIM ImmunoTech Inc
0.60
0.06 (11.11%)
Volume: 98,976
Day Range: 0.5301 - 0.5779
Last Trade Time: 8:00:00 PM EST

AIM
AIM ImmunoTech Inc
0.60
0.06 (11.11%)
Volume: 98,976
Day Range: 0.5301 - 0.5779
Last Trade Time: 8:00:00 PM EST

They have one fda approved drug patent has expired and Ampligen has been denied by fda. This is a good one one to get in after the rs and wait for the bottom. Just like Maple oil

This company looks like they have some good potential. I recently watched a doctor from Canada who is convinced by her teams studies that the Covid vaccines cause damage to TLRs 3,7, and 8 causing people to be more susceptible to illness. Their TLR 3 nasal spray might be extremely helpful in this case.

AIM
AIM ImmunoTech Inc
0.34
-0.0067 (-1.93%)
Volume: 196,446
Day Range: 0.322 - 0.35
Last Trade Time: 8:00:00 PM EST

AIM
AIM ImmunoTech Inc
0.6286
0.0708 (12.69%)
Volume: 176,005
Day Range: 0.5678 - 0.5797
Last Trade Time: 8:00:00 PM EDT
Total Trades: 323
AIM Detailed Quote

AIM
Aerosonic Common Stock ($0.40 Par Value)
3.19
0.00 (0.00%)
Volume: -
AIM Detailed Quote